Thomas M. Bridges
About
Thomas M. Bridges is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Computational Theory and Mathematics.
According to data from OpenAlex, Thomas M. Bridges has authored 102 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 91 papers in Molecular Biology, 64 papers in Cellular and Molecular Neuroscience and 7 papers in Computational Theory and Mathematics. Recurrent topics in Thomas M. Bridges's work include Receptor Mechanisms and Signaling (77 papers), Neuroscience and Neuropharmacology Research (58 papers) and Pharmacological Receptor Mechanisms and Effects (19 papers). Thomas M. Bridges is often cited by papers focused on Receptor Mechanisms and Signaling (77 papers), Neuroscience and Neuropharmacology Research (58 papers) and Pharmacological Receptor Mechanisms and Effects (19 papers). Thomas M. Bridges collaborates with scholars based in United States, Australia and Belgium. Thomas M. Bridges's co-authors include Craig W. Lindsley, P. Jeffrey Conn, Colleen M. Niswender, Carrie K. Jones, J. Phillip Kennedy, J. Scott Daniels, Patrick R. Gentry, Zixiu Xiang, Michael R. Wood and Corey R. Hopkins and has published in prestigious journals such as Chemical Reviews, Proceedings of the National Academy of Sciences and Journal of Neuroscience.
In The Last Decade
Thomas M. Bridges
102 papers receiving 3.0k citations
Peers
Thomas M. Bridges
Douglas J. Sheffler United States
Francine Acher France
Isabelle Brabet France
Robert R. Luedtke United States
Alice L. Rodriguez United States
Christian Tränkle Germany
Francesco Berardi Italy
David E. Nichols United States
Christopher J. Langmead Australia
Hyekyung P. Cho United States
Citations per year, relative to Thomas M. Bridges Thomas M. Bridges (= 1×)
peers
Douglas J. Sheffler
Countries citing papers authored by Thomas M. Bridges
Since
Specialization
Citations
This map shows the geographic impact of Thomas M. Bridges's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas M. Bridges with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas M. Bridges more than expected).
Fields of papers citing papers by Thomas M. Bridges
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Thomas M. Bridges. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas M. Bridges. The network helps show where Thomas M. Bridges may publish in the future.
Co-authorship network of co-authors of Thomas M. Bridges
This figure shows the co-authorship network connecting the top 25 collaborators of Thomas M. Bridges. A scholar is included among the top collaborators of Thomas M. Bridges based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas M. Bridges. Thomas M. Bridges is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Urata, H, Masaya Kokubo, Takahiro Mori, et al.. (2025). Discovery of ONO-2920632 (VU6011887): A Highly Selective and CNS Penetrant TREK-2 (TWIK-Related K+ Channel 2) Preferring Activator In Vivo Tool Compound. ACS Chemical Neuroscience. 16(5). 960–967.
2.
Engers, Julie L., Sichen Chang, Vincent B. Luscombe, et al.. (2024). Discovery of VU6008677: A Structurally Distinct Tricyclic M4 Positive Allosteric Modulator with Improved CYP450 Profile. ACS Medicinal Chemistry Letters. 15(8). 1358–1366.
3.
Engers, Julie L., Sichen Chang, Vincent B. Luscombe, et al.. (2024). Discovery of VU6016235: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M4 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM). ACS Chemical Neuroscience.
4.
Gregory, Karen J., Thomas M. Bridges, Rocco G. Gogliotti, et al.. (2019). In Vitro to in Vivo Translation of Allosteric Modulator Concentration-Effect Relationships: Implications for Drug Discovery. ACS Pharmacology & Translational Science. 2(6). 442–452.
5.
Temple, Kayla J., Julie L. Engers, Alison R. Gregro, et al.. (2019). Discovery of a novel 3,4-dimethylcinnoline carboxamide M4 positive allosteric modulator (PAM) chemotype via scaffold hopping. Bioorganic & Medicinal Chemistry Letters. 29(21). 126678–126678.
6.
Bender, Aaron M., Rebecca L. Weiner, Vincent B. Luscombe, et al.. (2017). Synthesis and evaluation of 4,6-disubstituted pyrimidines as CNS penetrant pan-muscarinic antagonists with a novel chemotype. Bioorganic & Medicinal Chemistry Letters. 27(11). 2479–2483.
7.
Engers, Julie L., Sichen Chang, Xiaoyan Zhan, et al.. (2017). Discovery of a novel 2,4-dimethylquinoline-6-carboxamide M4 positive allosteric modulator (PAM) chemotype via scaffold hopping. Bioorganic & Medicinal Chemistry Letters. 27(22). 4999–5001.
8.
Gogliotti, Rocco G., Jerri M. Rook, Ayan Ghoshal, et al.. (2016). mGlu5positive allosteric modulation normalizes synaptic plasticity defects and motor phenotypes in a mouse model of Rett syndrome. Human Molecular Genetics. 25(10). 1990–2004.
9.
Wood, Michael R., Meredith J. Noetzel, James C. Tarr, et al.. (2016). Discovery and SAR of a novel series of potent, CNS penetrant M4 PAMs based on a non-enolizable ketone core: Challenges in disposition. Bioorganic & Medicinal Chemistry Letters. 26(17). 4282–4286.
10.
Alcázar, Jesús, Silvia N. López, Hilde Lavreysen, et al.. (2015). Preliminary investigation of 6,7-dihydropyrazolo[1,5-a]pyrazin-4-one derivatives as a novel series of mGlu5 receptor positive allosteric modulators with efficacy in preclinical models of schizophrenia. Bioorganic & Medicinal Chemistry Letters. 26(2). 429–434.
11.
Bartolomé-Nebreda, José Manuel, Silvia N. López, Hilde Lavreysen, et al.. (2015). Discovery and SAR of novel series of imidazopyrimidinones and dihydroimidazopyrimidinones as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5). Bioorganic & Medicinal Chemistry Letters. 25(6). 1310–1317.
12.
Jones, Carrie K., Michael Bubser, Analisa D. Thompson, et al.. (2011). The Metabotropic Glutamate Receptor 4-Positive Allosteric Modulator VU0364770 Produces Efficacy Alone and in Combination with l-DOPA or an Adenosine 2A Antagonist in Preclinical Rodent Models of Parkinson’s Disease. Journal of Pharmacology and Experimental Therapeutics. 340(2). 404–421.
13.
Melancon, Bruce J., Thomas M. Bridges, Gary A. Sulikowski, et al.. (2011). Development of a more highly selective M1 antagonist from the continued optimization of the MLPCN Probe ML012. Bioorganic & Medicinal Chemistry Letters. 22(2). 1044–1048.
14.
Bridges, Thomas M., Evan P. Lebois, Corey R. Hopkins, et al.. (2010). The antipsychotic potential of muscarinic allosteric modulation. Drug News & Perspectives. 23(4). 229–229.
15.
Bridges, Thomas M., Joy E. Marlo, Colleen M. Niswender, et al.. (2009). Discovery of the First Highly M5-Preferring Muscarinic Acetylcholine Receptor Ligand, an M5 Positive Allosteric Modulator Derived from a Series of 5-Trifluoromethoxy N -Benzyl Isatins. Journal of Medicinal Chemistry. 52(11). 3445–3448.
16.
Bridges, Thomas M., J. Phillip Kennedy, Hyekyung P. Cho, et al.. (2009). Chemical lead optimization of a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) lead. Part I: Development of the first highly selective M5 PAM. Bioorganic & Medicinal Chemistry Letters. 20(2). 558–562.
17.
Jones, Carrie K., Ashley E. Brady, Albert A. Davis, et al.. (2008). Novel Selective Allosteric Activator of the M1Muscarinic Acetylcholine Receptor Regulates Amyloid Processing and Produces Antipsychotic-Like Activity in Rats. Journal of Neuroscience. 28(41). 10422–10433.
18.
Marlo, Joy E., Colleen M. Niswender, Emily Days, et al.. (2008). Discovery and Characterization of Novel Allosteric Potentiators of M1 Muscarinic Receptors Reveals Multiple Modes of Activity. Molecular Pharmacology. 75(3). 577–588.
19.
Lewis, L. Michelle, Douglas J. Sheffler, Richard D. Williams, et al.. (2008). Synthesis and SAR of selective muscarinic acetylcholine receptor subtype 1 (M1 mAChR) antagonists. Bioorganic & Medicinal Chemistry Letters. 18(3). 885–890.
20.
Brady, Ashley E., Carrie K. Jones, Thomas M. Bridges, et al.. (2008). Centrally Active Allosteric Potentiators of the M4 Muscarinic Acetylcholine Receptor Reverse Amphetamine-Induced Hyperlocomotor Activity in Rats. Journal of Pharmacology and Experimental Therapeutics. 327(3). 941–953.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Douglas J. Sheffler Breakdown of academic impact, for papers by Francine Acher Breakdown of academic impact, for papers by Isabelle Brabet Breakdown of academic impact, for papers by Robert R. Luedtke Breakdown of academic impact, for papers by Alice L. Rodriguez Breakdown of academic impact, for papers by Christian Tränkle Breakdown of academic impact, for papers by Francesco Berardi Breakdown of academic impact, for papers by David E. Nichols Breakdown of academic impact, for papers by Christopher J. Langmead Breakdown of academic impact, for papers by Hyekyung P. Cho